Preoperative (neoadjuvant) systemic treatment of breast cancer
- 31 December 2005
- journal article
- review article
- Published by Elsevier in The Breast
- Vol. 14 (6) , 576-581
- https://doi.org/10.1016/j.breast.2005.08.010
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast GroupJournal of Clinical Oncology, 2005
- Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival OutcomesJournal of Clinical Oncology, 2005
- In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot studyAnnals of Oncology, 2005
- The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2003
- Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerThe Lancet, 2003
- International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and RecommendationsJournal of Clinical Oncology, 2003
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Identification of high risk breast-cancer patients by gene expression profilingThe Lancet, 2002
- Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18JNCI Monographs, 2001
- Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6European Journal Of Cancer, 1994